North American Scientific Inc. (NAS) and Nomos Corp. will begin marketing each others radiation therapy products, prior to the closing of NAS' proposed acquisition of Nomos.
The companies anticipate closing their October 2003 transaction in the second quarter.
Under terms of the new agreement, Nomos immediately will begin to sell NAS' Prospera I-125 and Pd-103 brachytherapy sources. NAS' sales force will add the Nomos suite of intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) technologies.
Nomos' product line includes:
- Peacock, an IMRT planning and delivery system, which includes Corvus and Nomos' own multileaf collimator, MIMiC;
- Corvus, an IMRT inverse treatment planning system; and
- BAT, an IGRT product that uses ultrasound to confirm the location of target organs or tumors.
NAS President and CEO L. Michael Cutrer called the agreement "an important interim step" for the company, adding that it allows NAS "on an arms-length basis to capitalize on some of the complementary strengths of our respective organizations and broaden the exposure to increase market awareness of both parties' life-saving products."
NAS develops, produces and sells radioisotopic products, including brachytherapy seeds and radiopharmaceuticals.